0000950170-24-038721.txt : 20240329 0000950170-24-038721.hdr.sgml : 20240329 20240329164639 ACCESSION NUMBER: 0000950170-24-038721 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240328 FILED AS OF DATE: 20240329 DATE AS OF CHANGE: 20240329 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Miller Deborah Ann CENTRAL INDEX KEY: 0001868741 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40671 FILM NUMBER: 24804578 MAIL ADDRESS: STREET 1: C/O NUVALENT, INC. STREET 2: ONE BROADWAY, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nuvalent, Inc. CENTRAL INDEX KEY: 0001861560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE BROADWAY, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 508-446-2272 MAIL ADDRESS: STREET 1: ONE BROADWAY, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 ownership.xml 4 X0508 4 2024-03-28 0001861560 Nuvalent, Inc. NUVL 0001868741 Miller Deborah Ann C/O NUVALENT, INC. ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 false true false false Chief Legal Officer true Class A Common Stock 2024-03-28 4 M false 13000 18.93 A 46300 D Class A Common Stock 2024-03-28 4 M false 9000 27.85 A 55300 D Class A Common Stock 2024-03-28 4 S false 2748 74.23 D 52552 D Class A Common Stock 2024-03-28 4 S false 16208 75.22 D 36344 D Class A Common Stock 2024-03-28 4 S false 3044 75.94 D 33300 D Stock Option (Right to Buy) 18.93 2024-03-28 4 M false 13000 0 D 2032-01-04 Class A Common Stock 13000 89000 D Stock Option (Right to Buy) 27.85 2024-03-28 4 M false 9000 0 D 2033-01-06 Class A Common Stock 9000 102154 D These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 27, 2023. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.76 to $74.74, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.76 to $75.75, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.76 to $76.13, inclusive. The shares underlying this option vest as follows: 25% of the shares vested on January 4, 2023, and the remainder have vested or shall vest over the next three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date. The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date. /s/ Nathan McConarty, attorney-in-fact 2024-03-29